PDA

View Full Version : NIH Guide



Daniel Sheffer
06-30-1991, 10:56 PM
The most recent edition of the NIH GUIDE Volume 20(25) contains the
following announcement. The entire set of RFA's and guide may be
retreived from listserv at JHUVM in the files:

nihgde-l 91-00350 through nihgde-l 91-00355.

$$XID NIHGUIDE 19910628 V20N25 P1O1 ************************************

MOVEMENT DISORDERS

PA: PA-91-72

P.T. 34; K.W. 0715060, 0785035, 0785210, 0710100

National Institute of Neurological Disorders and Stroke

PURPOSE

An existing National Institute of Neurological Disorders and Stroke
(NINDS) Program Announcement, published June 6, 1980, is being reissued
to notify the scientific community of continuing NINDS interest in
movement disorders with particular emphasis on dystonia, tremor,
Parkinson's disease, and other basal ganglia degenerative disorders.
The emphasis on dystonia is in response to the 1991 House and Senate
Appropriations Reports. The NINDS invites grant applications to support
neurological research leading to a better understanding of the etiology
and pathogenesis of a variety of movement disorders, with the intent of
improving the early diagnosis and the treatment of these nervous system
dysfunctions and ultimately facilitating their prevention.

BACKGROUND INFORMATION

Neurological disorders of movement include dystonia, Parkinson's and
Huntington's diseases, other basal ganglia degenerations (such as
Progressive Supranuclear Palsy and Striatonigral Degeneration), and
other diseases of varied causation characterized by tics, tremors,
chorea, athetosis, and ballism. Most of these neurological disorders
are progressive and may be associated with dementia, ataxia, and other
neurological abnormalities, in addition to abnormal motor activity. In
some cases, the symptoms reflect abnormal function of specific brain
nuclei or classes of neurons; in others the abnormality is unknown. In
no case is the pathophysiological process adequately understood.

Dystonic movements can result from a number of causes. Typical torsion
spasms are twisting in nature and usually repetitive in occurrence. The
symptom severity and natural history are variable, making treatment
evaluation measures and prevalence estimates difficult. Essential
tremor is among the most common of all neurological disorders. It is
generally benign in course but may, at times, become a significant cause
of disability.

The individual cost of medical care in these neurological disorders and
the societal costs from lost or diminished function can be considerable.

RESEARCH GOALS AND SCOPE

Multidisciplinary and collaborative studies are encouraged.
Experimental studies may focus on anatomical, pathological, biochemical,
physiological, or pharmacological aspects of any of these diseases.

There is particular need for work in the following: (1) more precise
definition of the anatomical and/or physiological lesion; (2)
identification of characteristic abnormalities in non-neural tissues,
such as blood, skin, or muscle, that are more amenable to biopsy or
tissue culture; (3) development of animal models, experimental or
genetic, that mimic significant aspects of a movement disorder; (4)
molecular genetics; and (5) advanced neuroimaging research.

Existing therapies for the movement disorders are, in general,
unsatisfactory. Many drugs currently used are either ineffective over
long periods of time or associated with undesirable side effects. For
this reason, experimental therapeutic studies on animal models of
movement disorders and studies of appropriate in vivo systems are
encouraged.

MECHANISMS OF SUPPORT

Applicants may apply for the research project grant (RO1), research
program project (PO1), research center grant (P50), and First
Independent Research Support and Transition Award (R29). Prospective
applicants are encouraged to communicate with the Institute staff listed
at the end of the announcement regarding the appropriate funding
mechanism. Both basic science and clinical investigations are
encouraged to address relevant research issues.

APPLICATION AND REVIEW PROCEDURES

Applications must be prepared on form PHS 398 (revised 10/88) according
to instructions contained in the application kit. Application kits are
available from most institutional business offices and may be obtained
from the Division of Research Grants at the address given below:

Office of Grants Inquiries
National Institutes of Health
Division of Research Grants
Westwood Building, Room 449
5333 Westbard Avenue
Bethesda, MD 20892

Check "yes" in item two on the face sheet of the application and type
"Movement Disorders, PA-91-72."

Applicants for the P01 or P50 should use the application format as
described in the NINDS pamphlet, "Application Guidelines: Program
Project and Clinical Research Center Grants" (revised 10/89), that may
be obtained from the contacts listed under INQUIRIES.

Applications will be judged on scientific merit and program relevance in
accordance with NIH policy and procedures involving peer review. An
initial review will be made by an appropriate study section of the
Division of Research Grants for research grants and FIRST awards, and by
an appropriate institute committee for program projects and centers. A
second level of review will be made by an appropriate national advisory
council.

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements will be required to include
minorities and women in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder or
condition under study; special emphasis should be placed on the need for
inclusion of minorities and women in studies of diseases, disorders and
conditions which disproportionately affect them. This policy is
intended to apply to males and females of all ages. If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale should be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group. In addition, gender and
racial/ethnic issues should be addressed in developing a research design
and sample size appropriate for the scientific objectives of the study.
This information should be included in the form PHS 398 in Section 2,
A-D of the research plan and summarized in Section 2, E, Human Subjects.
Applicants/offerors are urged to assess carefully the feasibility of
incuding the broadest possible representation of minority groups.
However, NIH recognizes that it may not be feasible or appropriate in
all research projects to include representation of the full array of
United States racial/ethnic minority populations (i.e., Native Americans
(including American Indians or Alaskan Natives), Asian/Pacific
Islanders, Blacks, Hispanics).

The rationale for studies on single minority population groups should be
provided.

For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.

The usual NIH policies concerning research on human subjects also apply.
Basic research or clinical studies in which human tissues cannot be
identified or linked to individuals are excluded. However, every effort
should be made to include human tissues from women and racial/ethnic
minorities when it is important to apply the results of the study
broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application, the
application will be returned.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies. If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed and the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.

All applications for clinical research submitted to NIH are required to
address these policies. NIH funding components will not award grants or
cooperative agreements that do not comply with these policies.

Deadlines for the receipt of applications are February 1, June 1, and
October 1.

The original and six copies of the application must be sent directly to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**

INQUIRIES

For further information regarding this announcement, potential
applicants should write or call:

Philip H. Sheridan, M.D., Chief
Developmental Neurology Branch
Division of Developmental, Convulsive, and Neuromuscular Disorders
NINDS
Federal Building, Room 8C10
Bethesda, MD 20892
Telephone: (301) 496-6701

or

Eugene J. Oliver, Ph.D.
Division of Demyelinating, Atrophic, and Dementing Disorders
NINDS
Federal Building, Room 806
Bethesda, MD 20892
Telephone: (301) 496-1431

The program to which the intended grants relate is described in the
Catalog of Federal Domestic Assistance, entry number 93.853 - Clinical
Research Related Neurological Disorders, and 93.854 - Biological Basis
Research in the Neurosciences. Grants will be awarded under the
authority of the Public Health Service Act, Title IV, Section 301
(Public Law 78-410, as amended; 42 USC 241) and administered under PHS
grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part
74. This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.

$$P2 END ************************************************** *************

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS
THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.
APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE
ADDRESS FOR THE WESTWOOD BUILDING IS:

5333 Westbard Avenue
Bethesda, Maryland 20816

------------------------------------------------------------------
DANIEL B. SHEFFER, PH.D., HEAD BITNET R1DBS@AKRONVM
DEPARTMENT OF BIOMEDICAL ENG. INTERNET R1DBS@VM1.CC.UAKRON.EDU
UNIVERSITY OF AKRON TELEPHONE 216 972 6650
AKRON, OHIO 44325-0302 TELEFAX 216 374 8834